RGL2

Across TCGA pan-cancer cohorts, RGL2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RGL2 data layer compared with 25 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RGL2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RGL2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and HNSC show a favorable association.

PDAC, UCEC, and LUAD are the cancer types where RGL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	III,IV	0.266	0.641	.023	7	view →
UCEC	DFS	Tertile	II,III,IV	0.884	0.424	.021	6	view →
LUAD	DFS	Tertile	III,IV	0.471	0.995	.031	5	view →
HNSC	DFS	Tertile	III,IV	0.874	0.646	.020	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RGL2–PDAC (DFS)

Open the PDAC breakdown →